Wall Street
Price Targets

1AD Price Targets Summary
Adalta Ltd

There are no price targets for 1AD.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Adalta Ltd Competitors:
Price Targets
301080
Acrobiosystems Co Ltd
39% Upside
TLX
Telix Pharmaceuticals Ltd
128% Upside
4587
PeptiDream Inc
100% Upside
2157
Lepu Biopharma Co Ltd
106% Upside
FDMT
4D Molecular Therapeutics Inc
317% Upside
2696
Shanghai Henlius Biotech Inc
69% Upside
KURA
Kura Oncology Inc
204% Upside
ORKA
Oruka Therapeutics Inc
56% Upside

Revenue
Forecast

Revenue Estimate
Adalta Ltd

For the last 8 years the compound annual growth rate for Adalta Ltd's revenue is -12%. The projected CAGR for the next 4 years is 47%.

-12%
Past Growth
47%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Adalta Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Adalta Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is 1AD's stock price target?
Not Available

1AD doesn't have any price targets made by Wall Street professionals.

What is Adalta Ltd's Revenue forecast?
Projected CAGR
47%

For the last 8 years the compound annual growth rate for Adalta Ltd's revenue is -12%. The projected CAGR for the next 4 years is 47%.

Back to Top